

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
EXCLUSIVE SALES AGREEMENT OF
PENPULIMAB MONOCLONAL ANTIBODY

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has entered into an exclusive sales agreement of Penpulimab monoclonal antibody with its associate CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (正大天晴康方(上海)生物醫藥科技有限公司) (“**CTTQ-Akeso**”) and the associate’s shareholder Akeso Biopharma Co., Ltd. (中山康方生物醫藥有限公司) (“**Akeso Biopharma**”). Pursuant to the agreement, (i) the Group is authorized to be the sole sales agent of Penpulimab monoclonal antibody injection (PD-1 antibody (AK105) product, the “**PD-1 Monoclonal Antibody Product**”) in China, and is fully responsible for the market development and product promotion and sales of the PD-1 Monoclonal Antibody Product; and (ii) the Group will receive sales and marketing fees from CTTQ-Akeso, and procure the PD-1 Monoclonal Antibody Product from CTTQ-Akeso.

The PD-1 Monoclonal Antibody Product is co-developed by the Group and Akeso Biopharma, and has been granted marketing approval by the National Medical Products Administration of China, for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma after at least second-line systemic chemotherapy treatment. The entering into the exclusive sales agreement for Penpulimab monoclonal antibody will enable the PD-1 Monoclonal Antibody Product to take full advantage of the Group’s nationwide sales network and resources as well as its extensive experience in product promotion, which will be conducive to accelerating the commercialization of the PD-1 Monoclonal Antibody Product, benefitting more patients in China.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 20 December 2021

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.